Structural characterization of broadly neutralizing and potent V1/V2 apex antibodies elicited in rhesus macaques through immunization 2267435

Abstract Introduction Eliciting broadly neutralizing antibodies (bnAbs) that target the HIV-1 envelope glycoprotein (Env) remains a central goal of HIV vaccine design. Among these, antibodies directed against the V1/V2 apex epitope represent an important class of bnAbs with potent and broad neutralizing activity. As HIV-1 bnAbs often require extensive somatic hypermutation, a complete understanding of bnAb maturation pathways is essential to guide bnAb development during immunization. Methods Here, we combine negative-stain electron microscopy polyclonal epitope mapping (nsEMPEM) and cryo-electron microscopy (cryo-EM) to characterize potent and broad V1/V2 apex antibodies elicited in rhesus macaques immunized with the germline targeting immunogen CAP256.GT1. Results nsEMPEM analyses identified apex-targeting antibodies present in sera twelve weeks after the priming immunization, indicating successful engagement of desired precursor lineages. Polyclonal epitope mapping and biophysical characterization of antibody responses to candidate immunogens guided subsequent boosting strategies and successfully facilitated bnAb development. High-resolution cryo-EM structures of bnAbs isolated over a year after the priming immunization revealed that these antibodies recapitulate the binding modes and structural features observed in human-derived V1/V2 apex bnAbs isolated from chronically infected donors, further supporting the utility of nonhuman primate models for evaluating germline-targeting immunogens. Conclusion Together, these findings demonstrate the applicability of structural and polyclonal epitope mapping approaches in guiding rational vaccine design. Funding Source Howard Hughes Medical Institute Emerging Pathogens Initiative; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD); National Institutes of Health National Institute of Allergy and Infectious Diseases (NIH NIAID) Grants R01 AI 167716, R61 AI 161818, P01 AI 177683 Topic Categories Vaccines and Immunotherapy (VAC)